Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 8,388 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule Clear all
Completed Phase 3 Interventional Results available

Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

NCT00935012
View directory record Official record
Conditions
ATTR-CM, TTR-CM
Interventions
tafamidis
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Not applicable Interventional

Vitamin D for Muscle Metabolic Function in Cancer Cachexia

NCT03144128
View directory record Official record
Conditions
Cancer Cachexia, Vitamin D Deficiency
Interventions
Vitamin D, Placebo
Dietary Supplement
Lead sponsor
David Travis Thomas
Other
Eligibility
45 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Phase 1 Interventional

Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

NCT00591422
View directory record Official record
Conditions
Advanced Cancer
Interventions
ZIO-101-C (Darinaparsin)
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Ocoee, Florida • Dallas, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

NCT03836729
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir alafenamide/emtricitabine, GSK3640254
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Phase 1 Interventional

Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity Disorder

NCT00829881
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Betahistine Hydrochloride, Placebo Capsule
Drug
Lead sponsor
P2D, Inc.
Industry
Eligibility
22 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Body Weight, Aspirin Dose and Pro-resolving Mediators

NCT04697719
View directory record Official record
Conditions
Body Weight
Interventions
Aspirin 81mg, Aspirin 325mg
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Phase 3 Interventional

Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

NCT03456830
View directory record Official record
Conditions
Enteric Hyperoxaluria
Interventions
ALLN-177, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Phase 2 Interventional

Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease

NCT01073228
View directory record Official record
Conditions
Alzheimer's Disease, Central Nervous System Diseases, Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
50 Years to 85 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Phoenix, Arizona • Chino, California • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 29, 2026, 1:34 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

NCT05217628
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Basimglurant, Placebo
Drug · Other
Lead sponsor
Noema Pharma AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
La Jolla, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Results available

Combination Treatment Study for Memory Impairment and Depression

NCT01658228
View directory record Official record
Conditions
Depression, Mild Cognitive Impairment
Interventions
Donepezil, Placebo, Citalopram, Venlafaxine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 29, 2026, 1:34 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients

NCT01602367
View directory record Official record
Conditions
Hypertension
Interventions
BMS-823778, Placebo matching with BMS-823778
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
22
States / cities
Jonesboro, Arkansas • Los Angeles, California • Palm Springs, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 29, 2026, 1:34 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Precision Microbiota Interventions for Senoreduction Trial

NCT07462767
View directory record Official record
Conditions
HIV Infections, Alcohol Drinking, Aging, Immunosenescence
Interventions
Limosilactobacillus reuteri, Blueberry extract
Dietary Supplement
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
40 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 29, 2026, 1:34 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

The Effects of Psilocybin on Social Connectedness

NCT07693153
View directory record Official record
Conditions
Loneliness, Grief
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 29, 2026, 1:34 AM EDT
Not listed Phase 1 Interventional

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

NCT06399419
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, CBM588 Capsules, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Biological
Lead sponsor
Osel, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 29, 2026, 1:34 AM EDT
Recruiting Early Phase 1 Interventional

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

NCT05651828
View directory record Official record
Conditions
Advanced Basal Cell Carcinoma
Interventions
Vismodegib 150 MG Oral Capsule
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 29, 2026, 1:34 AM EDT
Terminated Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT00003497
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Phase 2 Interventional

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

NCT01112423
View directory record Official record
Conditions
Dyslipidemia
Interventions
BMS-823778, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Lenexa, Kansas • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

NCT00826280
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
regadenoson, overencapsulated caffeine, technetium, placebo
Drug · Radiation
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects

NCT00996879
View directory record Official record
Conditions
Hepatitis C
Interventions
Midazolam, BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

NCT01223027
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Dovitinib, Sorafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
34
States / cities
Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Not applicable Interventional

Ashwagandha for Nighttime Waking

NCT07151261
View directory record Official record
Conditions
Disturbed Sleep
Interventions
Ashwagandha, Placebo
Dietary Supplement · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects

NCT05232461
View directory record Official record
Conditions
Pharmacokinetics
Interventions
PrimeC-ER 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg
Drug
Lead sponsor
NeuroSense Therapeutics Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 29, 2026, 1:34 AM EDT
Withdrawn Not applicable Interventional

Monitoring the Effects of Probiotic Supplementation in Immunocompromised Kidney Transplanted Subjects

NCT05102461
View directory record Official record
Conditions
Diarrhea Caused by Drug, Dysbiosis
Interventions
Florajen Digestion Supplementation, Placebo Supplementation
Dietary Supplement
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 29, 2026, 1:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparing Blood Sugar Levels and Endothelial Function of PEAK ATP® With GlycoCarn®, PEAK ATP® and GlycoCarn® Supplements

NCT01855373
View directory record Official record
Conditions
Blood Sugar, Endothelial Function
Interventions
PEAK ATP® with GlycoCarn®, PEAK ATP®, GlycoCarn®, Placebo
Dietary Supplement · Other
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 29, 2026, 1:34 AM EDT